Novo Nordisk ADRs Climb After Study Suggests Its Wegovy Showed Heart Benefits
Novo Nordisk reported a study indicated its diabetes and weight-loss drug, Wegovy, helped reduce risks of heart attack, stroke, or death from cardiovascular disease.
( 1
min )